<DOC>
	<DOCNO>NCT02698735</DOCNO>
	<brief_summary>Recessive dystrophic epidermolysis bullosa ( RDEB ) incurable , devastate , inherit skin disease supportive care . RDEB due mutation COL7A1 gene encodes type VII collagen ( C7 ) , major component anchor fibril ( AFs ) mediate epidermal-dermal adherence . Approximately 20 % COL7A1 mutation nonsense mutation lead premature stop codon truncate C7 diminish function . The investigator demonstrate aminoglycosides gentamicin readily induce premature termination codon ( PTC ) `` read '' produce biologically functional C7 22 report COL7A1 nonsense mutation . Importantly , aminoglycoside-induced C7 reverse abnormal RDEB cell phenotype incorporate dermal-epidermal junction . Herein , investigator propose first clinical trial gentamicin ( topical intradermal ) RDEB patient nonsense mutation investigator fully characterize . The milestone include increased C7 AFs patient ' dermal-epidermal junction , improve RDEB Disease Activity Score , absence significant gentamicin side effect .</brief_summary>
	<brief_title>Gentamicin Therapy Recessive Dystrophic Epidermolysis Bullosa ( RDEB ) Nonsense Mutation Patients</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Patients recessive dystrophic epidermolysis bullosa ( RDEB ) bona fide nonsense mutation COL7A1 gene RDEB patient nonsense mutation COL7A1 gene</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>